Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic

References

• Bocchi EA. Heart failure in South America. Curr Cardiol Rev. 2013;9:147–156.
   PubMedGoogle Scholar
• Go AS, Mozaffarian D, Roger VL. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.
   PubMed Web of Science ®Google Scholar
• Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016–1022.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
   PubMed Web of Science ®Google Scholar
• Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 2001;80:213–219.
   PubMed Web of Science ®Google Scholar
• Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Heart Fail Clin. 2007;3:381–387.
   PubMedGoogle Scholar
• Yancy CW. Heart failure in African Americans. Am J Cardiol. 2005;96:3i–12i.
   PubMed Web of Science ®Google Scholar
• Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009; 54:375–385.
   PubMed Web of Science ®Google Scholar
• Guang C, Phillips RD, Jiang B, et al. Three key proteases-angiotensin-I-converting enzyme (ACE), ACE2 and renin-within and beyond the renin-angiotensin system. Arch Cardiovasc Dis. 2012;105:373–385.
   PubMed Web of Science ®Google Scholar
• Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837–2849.
   PubMed Web of Science ®Google Scholar
• Group TCTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429–1435.
   PubMed Web of Science ®Google Scholar
• Investigators TS. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293–302.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–677.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999;20:136–139.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362:772–776.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–1848.
   PubMed Web of Science ®Google Scholar
• Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141:693–704.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355.
   PubMed Web of Science ®Google Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390.
   PubMed Web of Science ®Google Scholar
• Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.
   PubMed Web of Science ®Google Scholar
• Groups TC-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
   PubMed Web of Science ®Google Scholar
• Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: beta-blocker CONtinuation Vs. INterruption in patients with congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30:2186–2192.
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
   PubMed Web of Science ®Google Scholar
• Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782–2795.
   PubMed Web of Science ®Google Scholar
• Investigators TB-BEoST. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;128:e240–e327.
   PubMed Web of Science ®Google Scholar
• Fowler MB, Lottes SR, Nelson JJ, et al. Beta-blocker dosing in community-based treatment of heart failure. Am Heart J. 2007;153:1029–1036.
   PubMed Web of Science ®Google Scholar
• Franciosa JA, Massie BM, Lukas MA, et al. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J. 2004;148:718–726.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Moullet C, Schon N, et al. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol. 2007;122:149–155.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Sinagra G, Opasich C, et al. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart (Br Cardiac Soc). 2003;89:299–305.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol. 2008;102:1524–1529.
   PubMed Web of Science ®Google Scholar
• Lopes RA, Neves FAR. Meta-analysis for bioequivalence studies: interchangeability of generic drugs and similar containing Hydrochlorothiazide is possible but not with Enalapril Maleate. J Bras Nefrol. 2010;32:173–181.
   PubMedGoogle Scholar
• Meredith PA. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin. 2009;25:2179–2189.
   PubMed Web of Science ®Google Scholar
• Smith JC, Tarocco G, Merazzi F, et al. Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Curr Med Res Opin. 2006;22:709–720.
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Shankar A, McManus RJ, et al. Evaluation of the management of heart failure in primary care. Fam Pract. 2009;26:145–153.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, SHIFT Investigators, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59:1938–1945.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184–192.
   PubMed Web of Science ®Google Scholar
• Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13:670–680.
   PubMed Web of Science ®Google Scholar
• Butler J, Khadim G, Belue R, et al. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Cardiac Fail. 2003;9:203–209.
   PubMed Web of Science ®Google Scholar
• Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail. 2006;8:302–307.
   PubMed Web of Science ®Google Scholar
• Gu D, He J, Coxson PG, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12:e1001860.
   PubMed Web of Science ®Google Scholar
• Yu B, Zhang X, Wang G. Full coverage for hypertension drugs in rural communities in China. Am J Manag Care. 2013;19:e22–e29.
   PubMed Web of Science ®Google Scholar